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1  | INTRODUC TION
Food allergies and their increasing prevalence have been the subject of 
intensive research in recent decades.1 Cow's milk allergy (CMA) is one 
of the most common food allergies. According to Finnish national re‐
cords and a cohort study in Europe, the incidence of challenge‐proven 
CMA is 0.5% in young children.2‐4 Although most children outgrow 
their milk allergies, children with severe milk allergies tend to have 
persistent CMA.5‐7 The recommended treatment for food allergies 
is allergy avoidance,1 but milk oral immunotherapy (OIT) has shown 
promise in promoting desensitization to cow's milk protein in children 
with persistent CMA.8‐12 Long‐term outcomes of milk OIT have been 
published in small studies, with success rates varying from 31% to 
65%.13‐15 More long‐term follow‐up studies on OIT are needed.8
This study was based on previous milk OIT studies conducted 
in Finland.12,15‐18 By gathering real‐life results from previous 
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Abstract
Background: The safety and efficacy of long‐term milk oral immunotherapy (OIT) in 
Finnish children with persistent cow's milk allergy (CMA) were evaluated in an open‐
label, non‐randomized study.
Methods: During	the	11‐year	study,	296	children	aged	5	years	or	older	with	immuno‐
globulin E (IgE)‐mediated CMA started milk OIT. Follow‐up data were collected at 
three time points: the post‐buildup phase, 1 year thereafter, and at the cross‐sectional 
long‐term	follow‐up	between	January	2016	and	December	2017.	Patients	were	di‐
vided according to baseline milk‐specific IgE (sIgE) level and by the amount of milk 
consumption	at	the	long‐term	follow‐up.	The	high‐dose	group	consumed	≥2	dL	of	milk	
daily, while the failure group consumed <2 dL of milk or were on a milk‐avoidance diet.
Results: Out of the initial study group, 244/296 (83%) patients participated in the 
long‐term	follow‐up.	Among	these	patients,	136/244	(56%)	consumed	≥2	dL	of	milk	
daily. The median follow‐up time was 6.5 years. Of the recorded markers and clinical 
factors, the baseline milk sIgE level was most associated with maintaining milk OIT 
(P < 0.001). Respiratory symptoms in the post‐buildup phase increased the risk of 
treatment failure (OR 3.5, 95% CI: 1.5‐8.1, P = 0.003) and anaphylaxis (OR 14.3, 95% 
CI: 1.8‐114, P = 0.01).
Conclusion: More than half of the patients were able to maintain the targeted milk 
dose in their daily diet. Baseline milk sIgE level and reactivity during the early treat‐
ment stage strongly predicted the long‐term outcome and safety of milk OIT.
K E Y W O R D S
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clinical studies, we were able to monitor the effects of milk OIT in 
296 patients over 11 years. We examined milk consumption over 
time, OIT safety, the reasons for OIT discontinuation, and the risk 
factors for treatment failure and anaphylaxis.
2  | METHODS
2.1 | Study design
An open‐label, non‐randomized milk OIT study started in 2005 
at the Skin and Allergy Hospital, Helsinki, Finland (Study Unit 
1).	 Study	Unit	 2	 started	milk	OIT	 in	2008	at	 the	Department	of	
Pediatrics, Tampere University Hospital. The two study units 
followed similar milk OIT protocols adapted from Meglio et al.9 
Briefly,	patients	aged	≥5	years	with	IgE‐mediated,	open	milk	chal‐
lenge‐positive CMA started milk OIT. Escalating doses of milk pro‐
tein were administered daily at home, starting from 0.5 µg to the 
maintenance dose of 6.4 g (approximately 2 dL of milk) during a 
4‐month buildup phase with daily antihistamine (Table S1).
2.2 | Follow‐up and data collection
Data	 were	 collected	 at	 three	 time	 points:	 (a)	 the	 post‐buildup	
phase, which occurred 3 months after reaching the maintenance 
dose (visit); (b) 1 year thereafter (visit; data not shown) or at the 
time when the patient discontinued treatment; and (c) a cross‐sec‐
tional	long‐term	follow‐up	between	January	2016	and	December	
2017 for all patients (mailed questionnaire or phone call if the 
patient	did	not	answer	 the	questionnaire).	Data	were	assembled	
from both the questionnaires and patient records. The patients 
were divided into three groups according to their long‐term milk 
consumption.	 The	 high‐dose	 group	 consumed	 ≥2	dL	 of	 milk	 per	
day (or equal amount of milk protein), while the failure group 
combined the low‐dose group (consumed <2 dL of milk or equal 
amount of milk protein) and the avoidance group (milk‐free diet). 
Anaphylaxes, as defined by the World Allergy Organization,19 
were determined from the questionnaires (both study units) and 
patient records (Study Unit 1).
2.3 | Ethics
The Institutional Ethics Committees of the Helsinki University 
Hospitals and the University Hospitals of Helsinki and Tampere ap‐
proved the study protocol and the follow‐up study. The follow‐up 
study was registered at ClinicalTrials.gov (number NCT02640014).
2.4 | Statistical analyses
Distributional	 differences	 in	 the	 clinical	 variables	 were	 compared	
with Fisher's chi‐square test and nonparametric Mann‐Whitney U 
test or Kruskal‐Wallis test. Kaplan‐Meier analysis was performed to 
measure the relationships between the participants who maintained 
milk OIT and their baseline milk‐specific IgE (sIgE) level with a log‐
rank test. The time to first discontinuation or the end of follow‐up 
was measured as the years since the patient began milk OIT as a time 
metric. Logistic regression analyses were used to define risk factors 
for OIT outcomes. Log2 transformation was assessed for sIgE level 
when needed. The reported P values are two‐tailed, when applica‐
ble, and values <0.05 were considered statistically significant. The 






patients in Study Unit 1 and 94 patients in Study Unit 2; Figure 1, 
Figure S1). Long‐term follow‐up data on milk consumption were avail‐
able for 244/296 (83%) patients. Among these patients, 136/244 
(56%)	consumed	≥2	dL	of	milk	daily,	44/244	(18%)	consumed	<2	dL,	
F I G U R E  1   The number of patients starting milk OIT each year divided by the number of patients participating through the follow‐up
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and 64/244 (26%) were on a milk‐avoidance diet. Table 1 presents a 
summary of the patients’ characteristics, grouped by their long‐term 
milk consumption.
Significant differences (P < 0.001) in the rates of milk OIT con‐
tinuance were noted when subjects with different baseline milk 
sIgE levels were compared (Figure 2). Logistic regression analysis 








(n = 64) P value
Baseline
Male sex 79 (58) 26 (59) 36 (56) 0.95
Age (years) when OIT was started 7.5 (5‐17) 7.0 (5‐14) 8.0 (5‐16) 0.24
Asthma 100 (74) 29/44 (66) 49/64 (77) 0.32
Atopic skin 86 (63) 36/44 (88) 42/63 (67) 0.12
Baseline milk IgE (kUA/L), data missing from 
1
12 (0.3‐9200) 26 (0.8‐942) 77 (2‐2450) 0.000
Baseline OFC cumulative threshold, milk 
protein dose (mg)a
396 (0‐5379) 99 (0‐2079) 10 (4‐20) 0.07
Adrenalin used at the baseline milk 
challenge
6 (4.4) 4 (9) 12 (19) 0.004
Post‐buildup phase results
Able to reach the high‐dose milk consump‐
tion (2 dL)
124 (91) 29 (66) 16/63 (25) 0.000
Presence of any milk‐related side effectsb 52/88 (59) 31/35 (89) 39/41 (95) 0.000
Treated with adrenalinb 1/88 (1.1) 1/36 (2.8) 2/42 (4.8) 0.45
Oral/ocular symptomsb 37/66 (56) 18/26 (69) 10/14 (71) 0.20
Cutaneous symptomsb 27/66 (41) 11/26 (42) 8/14 (57) 0.53
Respiratory symptomsb 26/65 (40) 18/26 (69) 10/14 (71) 0.01
GI symptomsb 30/66 (45) 19/26 (73) 11/14 (79) 0.01
Long‐term follow‐up results
Age (years) 14 (7‐25) 13 (8‐21) 14 (7‐24) 0.33
Long‐term follow‐up time (years) 6.5 (1‐11) 6.3 (1‐11) 6.4 (1‐11) 0.55
Current asthma 81/129 (63) 31/44 (70) 41/58 (71) 0.46
Cur. allergic rhinitis 91/127 (72) 30/43 (70) 40/56 (71) 0.97
Cur. atopic dermatitis 94/127 (74) 34/42 (81) 46/57 (81) 0.48
Average daily milk dose (median dL) 2.0 (2.0‐10.0) 1.0 (0.1‐1.5) 0.0 (0.0‐0.0) 0.000
Consuming only baked milk 1 (0.7) 3 (6.8) 0 (0) 0.01
Any milk‐related side effects in the past 
year
45/122 (37) 29/36 (81) 30/45 (67) 0.000
Treated with adrenalin 2/122 (1.6) 2/36 (5.6) 4/45 (8.9) 0.09
Oral symptoms 28/122 (23) 24/36 (67) 21/45 (47) 0.000
Cutaneous symptoms 21/122 (17) 17/36 (47) 17/45 (38) 0.000
Respiratory symptoms 20/122 (16) 21/36 (50) 17/45 (38) 0.000
GI symptoms 23/122 (19) 18/36 (58) 17/45 (38) 0.000
Anaphylaxis at least once after buildup 
(milk‐related)
9/131 (6.9) 6/43 (14) 19/60 (32) 0.000
Bold text represents statistical significance (P < 0.05).
High‐dose	group,	daily	milk	consumption	≥2	dL;	low‐dose	group,	0.1‐1.9	dL	milk	in	the	daily	diet;	and	avoidance	group,	milk‐avoidance	diet.	sIgE,	spe‐
cific	immunoglobulin	E;	OFC,	open	food	challenge;	GI,	gastrointestinal.	Details	for	side	effects	are	presented	in	Table	2.
Values are expressed as n (%) or median (range; min‐max).
aData	available	from	Study	Unit	1,	n	=	174	
bData	available	from	Study	Unit	1.	
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was conducted to define the effects of the baseline variables 
and the treatment‐related factors on milk OIT failure (Table 2). 
Other variables, such as gender, the age when OIT was started 
(<7 years vs older), baseline asthma, rhinitis, atopic disease, and 
the mother's atopic diseases, were examined, and none were 
statistically significant predictors of treatment failure (data not 
shown). The self‐reported, milk‐related respiratory symptoms in 
the post‐buildup phase were statistically significantly associated 
with higher median baseline milk sIgE level compared to the pa‐
tients with no respiratory symptoms (22.6 kUA/L [min 0.21 kUA/L‐
max 9200 kUA/L] vs 8.9 kUA/L [min 0.26 kUA/L‐max 942 kUA/L], 
P = 0.02, Mann‐Whitney U test). However, self‐reported, milk‐re‐
lated gastrointestinal (GI) symptoms in the post‐buildup phase 
were not statistically significantly associated with median base‐
line milk sIgE level compared to the patients with no GI symptoms 
(11.7 kUA/L [min 0.21 kUA/L‐max 9200 kUA/L] vs 10.6 kUA/L [min 
0.26 kUA/L‐max 9200 kUA/L] vs 10.6 kUA/L [min 0.26 kUA/L‐max 
942 kUA/L], P = 0.47).
3.2 | Safety
Side effect prevalence is presented in Table 1. Of the patients who 
participated	in	the	follow‐up,	77/244	(32%)	consumed	≥2	dL	of	milk	
daily with no self‐reported, milk‐related side effects in the previous 
year. The patients with longer follow‐up time tended to have less 
side effects, but the difference did not reach statistical difference 
(P	=	0.07;	Table	S2).	Anaphylaxes	after	 the	buildup	phase	were	 re‐
ported in 34/237 (14%) patients; data were missing from 59 patients. 
There was a significant difference in the baseline milk sIgE levels be‐
tween the patients who experienced anaphylaxis compared to the 
patients with no reported anaphylaxis after the buildup phase (me‐
dian 184 kUA/L [min 2.3‐max 1870 kUA/L] vs 14 kUA/L [min 0.3‐max 
9200 kUA/L], P = 0.000, Mann‐Whitney U test). Logistic regression 
analyses were conducted to further define the risk factors for ana‐
phylaxis (Table 2).
Eight patients reported using intramuscular adrenalin during the 
previous year in the long‐term follow‐up questionnaire. Two of the 
eight	had	been	consuming	≥2	dL	of	milk	for	over	9	years.	Both	had	
asthma and high baseline milk sIgE levels (>250 kUA/L). One of the 
anaphylaxes was related to unlimited milk consumption with exer‐
cise, and the other occurred after accidental exposure to an unfa‐
miliar milk product. There was one unexpected reaction related to 
the reduced daily milk dose (<2 dL) after 4 years of treatment, and 
one reaction in a patient who was still in the buildup phase at the 
time of the reaction. Four patients had an accidental reaction to milk 
while on avoidance diets and used adrenalin. One extremely severe 
anaphylaxis happened during the study. This reaction occurred after 
consumption of milk yogurt with a high concentration of cow's milk 
protein (8 g/100 mL), while he was on the aimed maintenance dose. 
This boy suffered from moderate‐to‐severe asthma and was experi‐
encing an exacerbation of that condition at the time of the anaphy‐
laxis. He had a high baseline milk sIgE level (>500 kUA/L). The subject 
required resuscitation and intubation but recovered fully without se‐
quelae; his milk OIT was discontinued.
3.3 | OIT discontinuation
A total of 71/252 (28%) patients discontinued milk OIT during the 
study period; the data were missing from 44/296 (15%) patients. 
Most patients (48/71, 68%) reported multiple reasons for discon‐
tinuation, with the most common self‐reported reason being GI 
symptoms (41/71, 58%). Reported GI symptoms included abdominal 
pain (16/41, 39%), nausea (15/41, 37%), vomiting (11/41, 27%), dys‐
phagia (8/41, 20%), and bloody stools (1/41, 2%). One patient with 
vomiting and failure to thrive had an endoscopy to check for possible 
eosinophilic esophagitis (EoE). The endoscopy results were negative 
for EoE, but the examination was performed after OIT discontinua‐
tion and while the patient was on a milk‐avoidance diet. Other rea‐
sons for OIT discontinuation included cutaneous symptoms (34/71, 
48%), respiratory symptoms (24/71, 34%), anaphylaxis (22/71, 31%), 
F I G U R E  2  Kaplan‐Meier	analysis	representing	the	relationship	between	milk	OIT	continuation	and	baseline	milk	sIgE	levels,	n	=	253.	
A log‐rank test was run to determine whether there were differences in the milk OIT continuation distribution for the different levels of 
baseline milk‐specific IgE, P	=	<0.001	(82%,	79%,	63%,	53%,	43%).	Time	(years)
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oropharyngeal side effects (21/71, 30%), disliking the taste of milk 
(7/71, 10%), ocular symptoms (5/71, 7%), no progress in the treat‐
ment (4/71, 6%), and miscellaneous symptoms (failure to thrive, 
trouble sleeping, taking milk was more demanding than avoidance, 
or behavioral changes such as tearfulness) (8/71, 11%). Median time 
since the beginning of the OIT to the discontinuation was 9 months 
(min 0‐max 76 months).
3.4 | Lost to follow‐up
Overall, 51/296 (17%) patients were lost by the time of the long‐term 
follow‐up (Figure S1). There was no statistical difference between 
the gender of the lost patients and those who participated in the 
long‐term follow‐up. The lost patients were older at the start of their 
milk OIT (median age 9 years vs 7 years, P = 0.038, Mann‐Whitney 
U test), and they had lower baseline milk sIgE levels compared to 
the patients who participated in the long‐term follow‐up (median 
8.5 kUA/L vs 18 kUA/L, P = 0.044, Mann‐Whitney U test).
4  | DISCUSSION
This report describes the results from 11 years of milk OIT in a clini‐
cal study based on real‐life experiences. More than half (56%) of the 
study participants maintained a high daily dose of milk consumption. 
However, some severe reactions occurred. Higher baseline milk sIgE 
level and early treatment reactivity strongly predicted the risk of 
treatment failure and anaphylaxis.
Previously published long‐term milk OIT studies have had 
small sample sizes, and the follow‐up time has varied from 4.5 
to 7 years.13‐15	 This	 study	 included	 a	 large	 sample	 size	 (n	=	296)	
with a median follow‐up of 6.5 years. We did not exclude children 
with high milk sIgE level or asthma. When necessary, a patient's 
asthma status was controlled before starting milk OIT. In a pre‐
vious milk OIT study, asthma was related to a worse long‐term 
outcome.20 Similarly, in our study, the presence of any type of 
milk‐related respiratory symptom in the post‐buildup phase in‐
creased the risk of treatment failure. Respiratory symptoms were 
associated with higher baseline milk sIgE level. Higher baseline 
tolerated milk amounts and not requiring adrenalin at the baseline 
food challenge have been identified as short‐term predictors for 
achieving a full milk dose.21 Our study reinforced these findings 
and extended these factors to long‐term predictors of maintaining 
a high milk dose.
The relationship between baseline milk sIgE level and milk OIT 
outcome has been previously published.14,15,18,22 This phenomenon 
has also been seen in the prevalence of children who outgrow their 
milk allergy5‐7 and in food challenges.23 A lower milk sIgE level is 
related to a better outcome. This study provides practical informa‐
tion for evaluating the risk of treatment discontinuation. Using this 
study, a patient with a certain baseline milk sIgE level can evaluate 
the likelihood of continuing treatment. When the baseline milk sIgE 
level was <10 kUA/L, 82% of the patients were able to consume milk, 
compared to baseline milk sIgE level over 150 kUA/L, where 43% of 
the patients were able to consume milk over time. However, care 
should be taken when applying the data presented in Figure 2, as 
TA B L E  2   Logistic regression analysis (using a log2‐transformed 
IgE concentration) of the milk OIT‐related variables and their 
relation to the milk OIT outcomes (analysis with one variable in the 








Milk sIgE before OITa 1.3 1.2‐1.5 0.000
Adrenalin used at 
the baseline milk 
challenge
3.8 1.4‐10 0.008





symptoms in the 
post‐buildup phaseb
1.3 0.6‐2.9 0.51















Milk sIgE before OIT 1.6 1.3‐1.8 0.000
Adrenalin used at 
the baseline milk 
challenge
2.0 0.7‐5.9 0.21





symptoms in the 
post‐buildup phaseb
3.4 0.98‐12 0.054




symptoms in the 
post‐buildup phaseb
14.3 1.8‐114 0.01
Bold text represents statistical significance (P < .05).
OIT, oral immunotherapy; sIgE, specific immunoglobulin E; GI, gastroin‐
testinal.	 Treatment	 failure—not	 able	 to	 maintain	 long‐term	 ≤2	dL	 milk	
dose.
a1.30 is the odds ratio for the baseline milk‐specific IgE level, indicating 
that for every additional doubling of the specific IgE level, the risk of OIT 
failure increases by 1.30 times or by 30%. 
bThe presence of any type (self‐reported) of oral symptoms (eg, itching, 
dryness/discomfort, swelling of the oral cavity, lips, tongue, and/or phar‐
ynx) or cutaneous symptoms (acute or delayed, eg, pruritus, erythema/
flushing, urticaria, angioedema, contact urticaria) or GI (eg, abdominal 
pain, nausea, emesis, vomiting, or dysphagia) or respiratory tract symp‐
toms (eg, nasal congestion, rhinorrhea, sneezing, hoarseness, laryngeal 
edema, dysphonia, shortness of breath, cough, or wheezing)27 related to 
milk	consumption,	data	available	from	Study	Unit	1,	n	=	105.	
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the numbers do not differentiate the amount of milk that the patient 
consumed.
The increased risk of EoE related to OIT has been highlighted in 
the literature. The rate of biopsy‐confirmed EoE in the analysis of 
multiple milk OIT studies was 5.4%.24 Notably, GI symptoms were 
the most commonly cited reason for patients discontinuing milk OIT. 
There are similarities between EoE symptoms and the symptoms 
that our patients reported (ie, failure to thrive, nausea, vomiting, 
abdominal pain, and dysphagia).24 An endoscopy was performed on 
one patient in the study group. The result of that endoscopy was 
negative for EoE, but the examination was performed when the pa‐
tient was on a milk‐avoidance diet. Our study revealed some intrigu‐
ing GI‐related associations. There was a strong correlation between 
self‐reported, milk‐related GI symptoms in the post‐buildup phase 
and treatment failure (P = 0.004), but unlike respiratory symptoms, 
GI symptoms in the post‐buildup phase were not associated with 
baseline milk sIgE level (P = 0.47). Parenthetically, the development 
of EoE is not driven by IgE.1
The reasons cited for milk OIT discontinuation in our study and 
the severe reactions related to milk OIT seen in our patients have 
both been described in the literature.25,26 One extremely severe re‐
action occurred during the study, and two patients reported having 
to use adrenalin after 9 years of daily milk consumption. These se‐
vere reactions were related to OIT protocol deviations (ie, consump‐
tion of a high‐milk protein product, unlimited milk consumption, 
and consumption of an unfamiliar milk product), and the affected 
patients had high baseline milk sIgE level and asthma. The EAACI 
guidelines highlight the crucial role of protocol adherence to ensure 
both safety and efficacy.27
There are limitations to our study. First, there was no control 
group, so the study cannot answer the question of how many of 
the studied children would have grown out of their allergies natu‐
rally without milk OIT. While it is highly possible that some patients 
might have improved on their own (especially the ones with low 
baseline milk sIgE level who tolerated larger amounts of milk pro‐
tein in the baseline OFC), our patients were above the age when 
milk allergies tend to resolve naturally,5 and CMA diagnosis was 
confirmed before the patients started OIT. It is also possible that 
some of our patients with low baseline milk sIgE level would have 
been able to introduce baked milk to their diet. Second, we did 
not study sustained unresponsiveness by performing treatment 
discontinuation and rechallenges. Likewise, milk consumption at 
the long‐term follow‐up was based on self‐reported questionnaire 
data.
The third limitation of our study was that 17% of the patients 
were lost during the long‐term follow‐up. The patients who were 
missing at the follow‐up had lower baseline milk sIgE level indicat‐
ing that their milk allergy might have been less severe. This dis‐
crepancy might have affected our results, as a larger portion of 
the study patients might be consuming milk over the long term 
than is reflected in our data. However, the study by Keet et al14 
reported that 22% (7/32) of patients were consuming milk with 
no symptoms over the long term, while in our study, 32% of the 
patients	were	 consuming	 ≥2	dL	 of	milk	 daily	 with	 no	 symptoms	
in the previous year. In addition, there were gaps in the follow‐up 
data due to the practicalities of collecting real‐life evidence. We 
also observed some unexpected changes in milk consumption over 
time (eg, 12 patients increased their milk consumption after the 
post‐buildup phase).
The strengths of our study include the large sample size, the fol‐
low‐up data collected over the course of up to 11 years, and the 
analysis of milk OIT in a real‐life setting. While long‐term safety has 
not been fully assessed in this field,27 this study provides practical 
knowledge on the long‐term use of milk OIT and highlights factors 
that might identify high‐risk patients. In this study, patients con‐
suming low daily doses of milk were placed in the treatment failure 
group along with patients who had discontinued milk OIT. However, 
the low‐dose group might still have benefitted from their milk con‐
sumption, as their self‐reported median milk dose was 32 times 
higher than their milk threshold level at the baseline milk challenge 
(Table 1).
In summary, this study suggests that OIT for the treatment of 
persistent milk allergy is most efficacious in patients with low base‐
line milk sIgE level. Baseline characteristics and early treatment 
reactivity strongly predicted the risk of later treatment failure and 
anaphylaxis. More than half of the patients were able to maintain 
a high daily dose of milk, and nearly three‐fourths of the patients 
continued at least some level of milk consumption.
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